Name: Zonisamide
Brand: Selleck Chemicals
SKU: S1445
Availability: InStock
Rating: 5 (2 reviews)

Jump to

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	CFTR CRM1 CD markers AChR Calcium Channel Potassium Channel GABA Receptor TRP Channel ATPase GluR
Other Sodium Channel Inhibitors	Camostat Mesilate A-803467 cariporide Veratramine Tolperisone HCl Bulleyaconi cine A Vinpocetine Tenapanor PF-06869206 Sparteine

Solubility

In vitro
Batch:

DMSO : 42 mg/mL (197.89 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 11 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	212.23	Formula	C₈H₈N₂O₃S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	68291-97-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Zonegran,CI-912,AD 810			Smiles	C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N

Mechanism of Action

Targets/IC₅₀/Ki	Sodium channel
In vitro	This compound inhibits monoamine oxidase B (MAO-B) activity in vitro with an IC(50) of 25 μM.
In vivo	Zonisamide modifies dopamine (DA) activity, provides protection in ischemia mice models and influences antioxidant systems. This compound attenuates the reduction in striatal contents of DA, its metabolite DOPAC and tyrosine hydroxylase (TH). It (10 and 30 mg/kg) produces antihyperalgesic and antiallodynic effects in a dose-dependent manner, these effects are manifested by elevation of the withdrawal threshold in response to a thermal (plantar test) or mechanical (von Frey) stimulus, respectively.. This chemical produces antinociceptive effects against acute thermal and mechanical nociception in non-ligated mice. It reduces the cortical infarction volume to 6% from 68% in vehicle-treated controls and the striatal volume to 8% from 78% in rats. This compound also reduces neuronal necrosis in 5 hippocampal regions (the dentate gyrus, CA4, CA3, CA1, and the subiculum) in rats. It causes increase in the quantity of EAAC-1 protein in hippocampus and cortex and down regulation of the GABA transporter GAT-1 in rats with hippocampal seizures. This chemical inhibits both the 50 mM KCl-evoked hippocampal glutamate release (AUC for 60 min) from 9.2 mM to 5.8 mM in urethane-anaesthetized rats, as well as the stimulatory effects of Ca2+ on KCl-evoked hippocampal glutamate release.
References	[1] https://pubmed.ncbi.nlm.nih.gov/19948168/ [2] https://pubmed.ncbi.nlm.nih.gov/16217643/ [3] https://pubmed.ncbi.nlm.nih.gov/8082694/ [4] https://pubmed.ncbi.nlm.nih.gov/12941455/ [5] https://pubmed.ncbi.nlm.nih.gov/9720801/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04774250	Terminated	Hearing Loss Noise-Induced	Washington University School of Medicine\|United States Department of Defense\|University of Texas\|Gateway Biotechnology Inc.	November 10 2021	Phase 2
NCT01830868	Completed	Partial Onset Seizures	Eisai Inc.	March 2012	--
NCT01283256	Completed	Partial Generalized and Combined Seizures	Eisai Inc.	January 2011	--
NCT01765608	Completed	Sleep Apnea\|Obstructive Sleep Apnea\|Obesity	Göteborg University\|Eisai Inc.	March 2010	Phase 2
NCT00203450	Completed	Obesity	Tuscaloosa Research & Education Advancement Corporation\|Eisai Inc.	May 2003	Phase 4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Zonisamide Sodium Channel inhibitor

Chemical Structure

Molecular Weight: 212.23